The following are recent financial reports as posted by selected Utah corporations:
HealthEquity
HealthEquity Inc., based in Draper, reported net income of $26.4 million, or 30 cents per share, for the quarter ended Jan. 31. The figures were the same for the prior-year quarter.
Revenue in the most recent quarter totaled $311.8 million, up from $262.4 million in the prior-year quarter.
For the full fiscal year, the company reported net income of $96.7 million, or $1.09 per share. That compares with $55.7 million, or 64 cents per share, for the prior fiscal year. Revenue in the most recent fiscal year totaled $1.2 billion, up from $999.6 million in the prior year.
HealthEquity is the nation’s largest health savings account custodian.
“‘Team Purple finished fiscal ’25 in strong fashion, with record revenues and major strides in advancing our strategic initiatives, allowing us to provide our outlook for an even stronger fiscal ’26,” Scott Cutler, president and CEO, said in announcing the results.
‘With a focus on member-first secure mobile experiences, we are executing against our ‘3Ds’ strategy to Deepen partnerships, Deliver remarkable experiences, and Drive member outcomes for our clients, network partners and members. We added a record 1 million new HSAs from sales this year and helped our nearly 10 million HSA members grow their HSA balances to over $32 billion.”
Sera Prognostics
Sera Prognostics Inc., based in Salt Lake City, reported a net loss of $8.6 million, or 25 cents per share, for the fourth quarter ended Dec. 31. That compares with a loss of $7.9 million, or 25 cents per share, for the same quarter a year earlier.
Revenue in the most recent quarter totaled $24,000, down from $41,000 in the year-earlier quarter.
For the full year 2024, the company reported a net loss of $32.9 million, or 99 cents per share. That compares with a loss of $36.2 million, or $1.16 per share, for 2023. Revenue in 2024 totaled $77,000, down from $306,000 in 2023.
Sera Prognostics is focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients.
“We are pleased with our progress during the year and, more recently, with the results of our full PRIME study,” Zhenya Lindgardt, president and CEO, said in announcing the results and referring to a recent risk assessment study.
“We are also thankful to our investors for supporting our fundraise last month, which we believe will promote our mission to mitigate the societal and health care costs of spontaneous premature birth and afford better outcomes for moms and babies by helping us drive adoption of our technology.”